Stéphanie Demoulin

Introduction: Stéphanie Demoulin, located in Antheit, Belgium, is a notable inventor recognized for his contributions in the field of biomedicine. With a single patent to his name, he has demonstrated a significant advancement that could change the landscape of thrombus treatment.

Latest Patents: Demoulin's patent, titled "Anticoagulant Fusion Proteins and Uses Thereof," discloses a fusion protein that includes a salivary gland polypeptide. This innovative fusion protein comprises at least one salivary gland polypeptide, one serum albumin polypeptide, and at least one linker peptide. The primary application of this invention is in the prevention or treatment of thrombus formation and growth, paving the way for new pharmaceutical compositions and medicaments.

Career Highlights: Currently, Demoulin is affiliated with Bioxodes, where he continues to explore and develop groundbreaking ideas in biomedicine. His research emphasizes the intersection of protein engineering and therapeutic applications, showcasing his commitment to improving healthcare solutions.

Collaborations: Throughout his career, Stéphanie has collaborated with esteemed colleagues such as Edmond Godfroid and Michel Guyaux. These partnerships have further enriched the innovative environment in which he operates and have contributed to the success of his projects.

Conclusion: Stéphanie Demoulin stands out as an inventor whose work in anticoagulant fusion proteins holds great promise for the medical community. His patent exemplifies the potential of innovative research to impact real-world health issues. As he continues his journey at Bioxodes, the future of biomedicine looks bright with his contributions.

Profile summary based on public USPTO records.